Trial intelligence / Profile preview

CAINTA trial of individualized cabazitaxel dosing in advanced castration-resistant prostate cancer

2013-005504-34Phase 2Completed

Sponsor: Central European Society for Anticancer Drug Research
Start: Jun 2014
Modality: Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
Countries: 1

Overview

Phase 2, randomised, open-label trial of cabazitaxel in castration-resistant prostate cancer (CRPC) (2 arms), sponsored by Central European Society for Anticancer Drug Research. Primary endpoint: Clinical feasibility rate. Started Jun 2014; status: completed.

Drugs

cabazitaxel

Conditions

castration-resistant prostate cancer (CRPC)

Beyond the preview

Go deeper on 2013-005504-34.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2013-005504-34.